MET and non-small cell lung carcinoma: Herein, we conducted a MS-based, data-independent acquisition (DIA) quantitative proteomic approach to explore the blood-based proteomic profiles to determine predictive biomarkers for MET-dysregulated NSCLC patients treated with MET inhibitors.